ArticleJournal of pathology informatics2026
Hierarchical vision transformers for Epstein-Barr virus status and histological subtype prediction in Hodgkin lymphoma whole-slide images.
Article in Journal of pathology informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Accurate stratification of Hodgkin lymphoma (HL) by immunologic/histological subtypes and Epstein-Barr virus (EBV) status is essential for epidemiological and translational research, yet large-scale testing is impractical and expensive. Digital pathology models that utilize routinely used hematoxylin and eosin (H&E) whole-slide images (WSIs) could close this gap. We developed and validated a hierarchical Vision Transformer pipeline that aggregates cell-, patch-, and region-level context to predict EBV status and the three most prevalent immunological/histological HL subtypes: nodular sclerosis (NS), mixed cellularity (MC), and nodular lymphocyte-predominant HL (NLPHL)-from H&E-stained WSIs, and additionally evaluated a standard attention-based multiple-instance learning (ABMIL) baseline for direct architectural comparison. The development pool comprised 1643 HL cases (1952 WSIs) from 18 Danish hospitals and was used for hospital-preserving 5-fold cross-validation; external validation was performed on an independent hold-out cohort of 458 cases (532 WSIs) from five hold-out hospitals. For subtype prediction, analyses were restricted to the 1560 cases belonging to NS, MC, or NLPHL. On the external EBV cohort (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.